Skip to content
Learn More

Resources

Changing the Paradigm of Cancer Drug Discovery and Development with Plants

May 2, 2022

In this article, iBio’s Chief Scientific Officer, Martin Brenner, DVM, Ph.D.; Chief Operating Officer, Randy Maddux; and oncology pipeline advisor, Steven King, explore how the iBio Drug Discovery Center is using the FastPharming System® to support faster and more efficient development of powerful new weapons in the battle against cancer.

Learn More

FastPharming Technology Used to Grow Plants for Discovering Developing and Manufacturing New Drug Candidates with Tom Isett iBio

March 9, 2022

Tom Isett is the CEO of iBio which is pioneering the next generation of biopharmaceuticals. Their goal is to reduce the cost, time, and risk of failure involved with drug discovery and development by using a plant-based recombinant protein manufacturing platform to create small and large batches of desired proteins. Tom shares his career journey from working with the USDA to iBio where he is back to working with the little leafy green guys again.

Tom explains, “We are a biotech, so we’re a developer of biopharmaceuticals, specifically focused in oncology, fibrosis, and infectious diseases, where we’re really trying to address some of the bigger unmet medical needs out there. But what I think really makes us unique is how we develop these new medicines, molecules, and candidates. We use plants to produce these new drug candidates.”

Learn More

Plant-Based Biologics With iBio’s Randy Maddux

February 17, 2022

iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma’s attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company’s FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.

Learn More

Vaccine Manufacturing: Chasing COVID’s Long Tail

January 31, 2022

By Mid-December 2021, the RAPS (Regulatory Affairs Professionals Society) COVID-19 Vaccine Tracker listed 91 active COVID-19 candidates in development around the globe. That’s in addition to the 25 vaccine products already approved by various international regulatory authorities.

Just months ago, one might have questioned the business case for jumping into – or even remaining in – that crowded race.

Then, along came Delta. And Omicron after that. And then the ensuing questions—and lack of immediate answers—about the Moderna, Pfizer, and J&J products’ efficacy against mutations, or how many doses of each it might take to achieve protection from these emerging variants. And the next one. And the one after that. Because the next mutation isn’t an if proposition so much as a question of when it’s detected. It’s already out there, somewhere.

Learn More
Top